Ausgabe 6/2023
Inhalt (8 Artikel)
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India
Ankit Patel, Niraj Bhatt, S. S. Prakash, Ghanashyam Biswas, Rajnish Nagarkar, Bodhisatta Roy, Priyanka Samal, Narendra Agrawal, Sushil Meshram, Ashish Kaushal, C. T. Satheesh, Ravikumar Wategaonkar, Kasi Viswanathan Thiagarajan, Kartikeya Jain, P. Vijayaveeran, Kalyan Mukherjee , Kishore Singh, Tushar Patil, Amit Jain, Tuphan Kanti Dolai, Minish Jain, Sachin Hingmire, Tara Chand Gupta, K. C. Lakshmaiah, Deepan Rajamanickam, Bhushan Nemade, Vikash Goyal, Pinaki Mahato, Sanjeev Kumar Mendiratta, Maulik Doshi
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, Akiko Todaka, Takeshi Kawakami, Damijan Erzen, Akiko Sarashina, Bin Li, Jianrui Hou, Kentaro Yamazaki
Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients
Yusuke Suzuki, Takafumi Naito, Kaito Shibata, Seiji Hosokawa, Junichi Kawakami
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor
Seong Jang, Bill Strickland, Lynda Finis, Jeffrey J. Kooijman, Janneke J. T. M. Melis, Guido J. R. Zaman, Jan Van Tornout
The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database
Masami Tsuchiya, Taku Obara, Masafumi Kikuchi, Nariyasu Mano
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy
Samantha K. Korver, Joanne M. Bowen, Rachel J. Gibson, Imogen A. Ball, Kate R. Secombe, Taylor J. Wain, Richard M. Logan, Jonathan Tuke, Kelly R. Mead, Alison M. Richards, Christos S. Karapetis, Dorothy M. Keefe, Janet K. Coller
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers
Chaoying Hu, Yanping Zhang, Tong Pei, Ping Liu, Lan Zhang